Citi still bullish on Ambit despite no AA for quizartinib

|About: Ambit Biosciences Corp (AMBI)|By:, SA News Editor

Citi maintains a Buy rating on Ambit Biosciences (AMBI -35.2%).

Although Citi reportedly says AA for quizartinib wasn't baked into the share price, today's sell-off seems to tell a different story.

Price target lowered to $17 from $19.